PrEP (pre-exposure prophylaxis) is a new HIV prevention intervention. PrEP Watch is a clearinghouse for PrEP data, additional research, cost, access and advocacy efforts across the globe.
Communities across the globe are at varying stages of implementation of daily oral PrEP. TDF/FTC is approved for use as oral PrEP in a handful of countries, and access is expanding globally. In some places there is growing uptake; in others, access is limited to pilot projects. Other countries are not yet exploring implementation. Learn more about access and advocacy below.
Daily oral PrEP involves drugs that are also used in HIV treatment. This means the strategy may only be available via off-label use in some places. Much work is needed to see innovative, impactful introduction.
June 22, 2016
More than 49,000 people in the US have filled prescriptions for Truvada for PrEP at retail pharmacies, according to the results of a survey by Gilead Sciences. Among PrEP users with available data, most were white gay men. Black people used PrEP much less often, despite having the highest rates of HIV infection.
June 20, 2016
An aidsmap summary of additional data from the Partners PrEP trial in serodiscordant couples showing that intimate partner violence affects adherence—a finding that also exists for people taking ART as HIV treatment.
June 20, 2016
MAC AIDS Fund has announced a two-year commitment to educate African-American women in DC about PrEP and promote its use by getting more health-care providers, including public clinics, to prescribe it.
June 13, 2016
The Southern HIV/AIDS Strategy Initiative released a report to increase PrEP uptake in the United States, specifically in the South. The report includes recommendations for government at the local, state and federal levels as well as proposals for Gilead Sciences, the maker of Truvada.